PubMed Health⌕ Search

Biomedical subjects

G Nyerges

Publications and source records attributed to G Nyerges.

At least 19 recordsLinked to original sources
PubMed1993

[Significance of varicella zoster infection in pregnancy and labor].

The authors observed 25 pregnant or delivering women with varicella and their offsprings from 1986 to 1991. The course of varicella of the pregnant and delivering mothers was generally benign, only one progressive case was observed with pneumonitis after delivery; this woman also recovered upon acyclovir treatment. All but one woman delivered on term, in one case the varicella developed on the 27th gestational week; this woman gave birth to a premature baby of 1180 g who died from a cerebral and lung hemorrhage. No sign of varicella-zoster virus infection was found at the autopsy. No congenital varicella syndrome was observed during the investigation period. Varicella-zoster immunoglobulin was given to 21 newborn babies, immediately after birth. Eight of the newborns developed varicella, the course of the disease was mild in seven cases. One baby who was given no varicella-zoster immunoglobulin and developed progressive varicella recovered after acyclovir therapy. During the investigation period the authors observed three cases of zoster in infants whose mothers had had varicella during pregnancy. The authors discuss the possibilities of prevention of varicella-zoster virus infection of newborns and infants.

Acyclovir↗
PubMed1993

[Hearing loss resulting from purulent meningitis in the light of adjuvant dexamethasone therapy].

Results of objective audiometry of 109 infants and children after purulent meningitis are presented. Among them 17 patients got dexamethasone as a supportive therapy. There was no statistically significant difference in hearing loss between the dexamethasone-treated and the control group. (41 vs 43% sensorineural hearing loss respectively). Authors do not contraindicate the dexamethasone therapy in purulent meningitis because of its harmlessness and useful effect to the course of the disease but further investigations are needed for avoidance of hearing loss following meningitis.

Chemotherapy, Adjuvant↗
PubMed1993

Oral acyclovir to prevent dissemination of varicella in immunocompromised children.

Twenty-five immunocompromised children with varicella were treated with oral acyclovir 800 mg, five times daily for 7 days. Two patients were transferred from the oral to the intravenous route: one had signs of varicella pneumonitis on routine X-ray, the other had continuing new lesion formation on day 4 of oral treatment. The disease healed in all patients, with no other evidence of dissemination. In an historical placebo treated group, 12 of 25 patients were transferred to intravenous acyclovir. The reduction to two of 25 is statistically significant (P < 0.01). The mean peak plasma acyclovir concentration in these patients was 6.56 mumol/l. Mild, self-limiting diarrhoea in nine patients was the only adverse event considered to be related to acyclovir. It is concluded that immunocompromised children with varicella can be treated safely and effectively with oral acyclovir. All patients should be observed closely by a physician.

Acyclovir↗
PubMed1990

Early relapses of varicella-zoster virus infection in immunocompromised children treated with acyclovir.

Authors observed one or more early VZV relapses in 8 out of 98 Acyclovir treated immunocompromised children with varicella. None of the 8 children developed VZV antibodies by the end of the 5-day ACV treatment. All VZV relapses were successfully treated with ACV or Vidarabine, but were stopped only after the appearance of VZV antibodies in the patients' sera. The possible role of ACV treatment in pathogenesis of early VZV relapses could be excluded by comparing the VZV antibody production of patients treated with ACV from the first day of varicella on with the antibody response of those, who received ACV as late as on the 5th day of varicella. By prolonging the ACV treatment till the appearance of VZV antibodies, early relapses could be avoided.

Acyclovir↗
PubMed1989

[Incidence and characteristics of childhood suppurative meningitis in Hungary in 1983-87].

Data of 1208 infants and children hospitalized for purulent meningitis were analysed. The incidence of the disease was closely age related: morbidity calculated for 100,000 children was found 97.5 under one year of age; 15.6 in 1 to 5 and 2.2 in 6 to 14 years of age. Incidence of newborn meningitis cases was 3.7 per 10,000 live-borns. The disease was caused by N. meningitidis in 278 (23%), H. influenzae in 171 (14%), S. pneumoniae in 157 (13%), E. coli in 74 (6%), B-group streptococcus in 61 (5%), other bacteria (altogether 17 species) in 107 (9%) cases, while in 360 cases (30%) the etiology remained unknown. Overall case fatality was 19.6 per cent. When compared to international data mortality was especially high among the newborns (53%) and in meningitis cases due to S. pneumoniae (29%), E. coli (48%), B-group streptococcus (37%) and "other bacteria" (41%). Neurologic sequelae were found in 17 per cent of the patients at discharge however, in newborns it was 54 per cent. Since the antibacterial therapy was appropriate in all cases, authors try to reveal the possible causes of the relatively high mortality and make recommendations for reducing it.

Adolescent↗
PubMed1988

Treatment of chickenpox in immunocompromised children.

In Hungary since 1981, 98 immunocompromised children have been treated with intravenous acyclovir for varicella zoster virus infections. They were treated in an open study or a double-blind study. Results of both are discussed briefly. Overall, five of 74 patients with varicella died, whereas all 24 patients with herpes zoster recovered. Treatment failures occurred in patients in whom treatment started late and in those with severe lymphocytopenia. In some children, varicella zoster virus-specific antibodies failed to develop by the end of treatment, and a proportion of these suffered recurrent episodes of varicella.

Acyclovir↗
PubMed1988

Acyclovir prevents dissemination of varicella in immunocompromised children.

Fifty immunocompromised children with varicella who exhibited no signs of dissemination were treated with intravenous acyclovir or placebo in a double-blind, randomized study. Twelve of 25 placebo recipients were withdrawn from treatment because of their deteriorating condition and were given open acyclovir therapy; only one of 25 recipients of acyclovir was similarly withdrawn (P less than .001). Among those patients who did not receive open treatment, acyclovir significantly reduced time to full crusting (P = .01). Overall, acyclovir, as judged by the physician, significantly improved the patients' condition.

Acyclovir↗
PubMed1986

A comparison of combined diphtheria, tetanus and pertussis vaccines produced by different manufacturers, in laboratory animals and in infants.

Three DTP vaccines were investigated for potency and toxicity (reactogenicity) both in laboratory animals and in infants. Animal tests were carried out in conformity with the WHO recommendations. Three- to five-month-old infants were investigated for their specific antibody responses and for local and systemic vaccination reactions. No correlation was found between the potency values of the vaccines as expressed in IUs and the antibody titres of the vaccinated infants. The most striking difference between the human and animal responses to vaccination was observed in the case of the tetanus toxoid. The severity of the vaccination reactions in infants correlated with the toxicity of the vaccines as assessed in the mouse weight gain test (MWGT) carried out in CBA mice. No correlation was found, however when conventional or AKR mice were used in the MWGT.

Animals↗
PubMed1986

Significance of the number of viable units in BCG vaccines.

The objective of the study was to establish the incidence of suppurative lymphadenitides in newborns vaccinated with BCG vaccines of different strength and to investigate the postvaccination tuberculin positivity of the children involved in the study. Lyophilized vaccines prepared from the Pasteur strain were used. Altogether 51,000 children were included in the study. One group, consisting of 30,000 newborns was vaccinated with a BCG lot containing 2 X 10(5) viable units (VU) per dose. The other group, consisting of 21,000 newborns, was given a BCG lot containing 0.5 X 10(5) VU per dose. The incidence of suppurative lymphadenitides per 1,000 vaccinated infants was 6.84 and 0.87 in the two groups, respectively. Tuberculin tests were carried out 2 years after the vaccination. Two units of RT-23 tuberculin were used. In 3,821 children vaccinated with the stronger vaccine the rate of tuberculin positivity was found to be 19.8 per cent, while it was 16.4 per cent among 5,035 children who had been given the weaker lot.

BCG Vaccine↗
PubMed1984

The second international standard for tetanus toxoid (adsorbed).

The stocks of the first International Standard for Tetanus Toxoid, Adsorbed are exhausted and a second International Standard was established in 1981. An international collaborative assay arranged to calibrate the second International Standard revealed that the first and the second International Standards are not strictly comparable. It is indicated that the problems encountered are general problems in the potency assay of adsorbed tetanus toxoids.

Adsorption↗